echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Investor's perspective , the new three-board turn-around rules come out, medical and health "source" rich

    Investor's perspective , the new three-board turn-around rules come out, medical and health "source" rich

    • Last Update: 2020-12-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Eight departments jointly issued a message to promote Guangdong, Hong Kong, Macao, Greater Bay Area drug medical device regulatory innovation and development of the second batch of medical supplies centralized procurement of the upcoming Ministry of Industry and Information Technology United Nations Health Care Commission to organize the implementation of 5G plus medical health application pilot project declaration work please pay attention to this week's pharmaceutical investment and financing weekly report! Business-Follow us deal summary Biopharmaceuticals this week: There were seven private placements, two mergers and acquisitions and one IPO in the biopharmaceutical sector this week.
    private placements, Huayu Zhongtian completed rmb890m of Pre-IPO round financing, unknown Jun completed tens of millions of dollars of B-plus round of financing, mergers and acquisitions, Mercado will buy Oncolmmune with $425m in cash advances, and IPO, East Asia Pharmaceuticals listed on the Shanghai Stock Exchange.
    : There were seven private placements, one merger and acquisition and one IPO this week.
    Private equity, Xianjian Technology completed equity financing, Waugh Medical completed hundreds of millions of yuan C round financing, Boji Medical completed hundreds of millions of yuan B round financing, Coke Life Sciences completed hundreds of millions of yuan B round financing, Yuan heart technology completed 160 million yuan A round financing, Wick Medical completed tens of millions of yuan A round financing, Rite-Hit Technology completed tens of millions of YUAN A round of financing, mergers and acquisitions, Vigo shares proposed to increase the capital of a total of 66.11 million yuan to buy all of Vigo Pry; In terms of IPOs, Tianyi Medical Exchange GEM IPO filed an application.
    IVD and Precision Medicine: There are 4 private financings in IVD and Precision Medicine this week.
    private placement, hemoproteomics testing research and development developer SomaLogic completed $121 million A round of financing, gene testing service provider Main Gene completed 541.64 million yuan equity financing, IVD reagent raw materials and overall solutions service provider Bo Yue Bio completed tens of millions of yuan angel round financing, chemical luminescent immunodiagnosis service provider Sanlian Bio completed tens of millions of yuan of Pre-IPO round financing.
    : There were two private financings in the healthcare sector this week.
    Kunya Medical completed hundreds of millions of yuan C round financing, Hao Yue Capital as the exclusive financial advisor, community health chain brand Johnson Medical completed hundreds of millions of yuan C round financing.
    : There are 5 private financings and 1 merger and acquisition transaction in the smart healthcare sector.
    Private placement, JD.com Completed $1.36 billion in strategic financing, Waterdrop Mutual completed $150 million strategic financing from Tencent Holdings, B2B Pharmaceutical e-commerce company Quanyuantang completed RMB500 million in round C financing, and in the merger, Huano Zhisheng, which focuses on digital diabetes management, and Yikang Delta, a digital weight management company, completed the merger.
    This week's key news review of the new three boards of the board rules out, medical health "source" rich news summary: November 27, the Shanghai Stock Exchange, Shenzhen Stock Exchange has issued the "National Small and Medium-sized Enterprises Share Transfer System listed companies to the Shanghai Stock Exchange Section of the board change board" The Listing Measures (Trial) and the Measures for listing companies listed on the National Small and Medium Enterprises Share Transfer System to the GEM board of the Shenzhen Stock Exchange (Trial) clearly define the conditions, audit mechanism and procedures and listing bridging arrangements for the listing of the new three-board selected tier listed companies to the Board or GEM.
    as a whole, the trans-plate should be listed continuously in the selected layer for more than 1 year, transferred to different plates to meet the positioning of the intention plate.
    The Shanghai-Shenzhen Stock Exchange has made detailed provisions on the conditions of the board: the board should meet 5 basic conditions and 2 unique conditions designed for the listing of the board, of which the basic conditions are consistent with the conditions of the board or GEM IPO.
    Investor's Perspective: From the implementation of the tiered program in 2016 to June 3, 2020, the CSRC issued "guidance on the national small and medium-sized enterprise share transfer system listed companies on the board" and the release of the implementation rules, the new three-board "turnboard" listing system through 4 years of innovation and evolution.
    The landing of the market on the board has added a new path of "new three-board innovation layer - selected layer IPO-A-share" to the IPO, activated the new three-board market, which was already lacking in vitality, and changed the way the new three-board enterprises "delisted the new three-board - apply for A-share IPO".
    as of November 20, 2020, 46 new three-board companies have been delisted and 14 have been listed.
    the detailed rules, for technology and innovative enterprises, after entering the select layer can directly apply for the board listing transactions, more to speed up the listing process.
    new three-plate selection layer was established and opened on July 27, 2020, meaning that select tier companies can apply for a switch as soon as the end of July next year.
    36 companies listed in select tiers as of November 27, according to the National Stock Exchange.
    by market capitalisation, 19 of them exceeded the market capitalisation threshold of 1 billion for the Board and GEM, with healthcare companies occupying six seats.
    the first batch, more qualified health care companies will be added to the selection of layer-turning boards.
    Integrated Wind and Choice data classification, as of the end of October 2020, the new three-board sample pool of 563 health care companies, including the innovation layer and the basic layer according to one of the selected tier market value / revenue / profit criteria preliminary screening is expected to be 96 into the list of candidates, contributing to a large number of A-share IPO potential "source".
    overall, the landing of the new three-board turnboard makes the multi-level capital market framework further established, the supply-side registration system plus the board landing, providing a number of alternative paths for enterprise securitization.
    Private equity financing Huayu Zhongtian Pre-IPO round: 890 million yuan investment institutions: (lead investment) Yifeng Capital, Weiwei China, (with investment) Jianyin International, China National Pharmaceutical Co., Ltd., Tiancheng Capital, Chengdu Biocity and other company profile: the company was founded in 2002, located in Beijing.
    is a company focused on the research and development and production of anti-tumor small molecule chemical drugs, mainly engaged in the development of anti-tumor small molecule chemical drugs biopharmaceuticals, while engaged in protein phosphatase PP2A specific inhibitor Fostriecin derivatives and protein phosphatase PP1 specific inhibitor variants of the development of mycobacterial derivatives, the main products for the new ERBmycin drug UTD1 and anti-tumor innovation drug Demethilone.
    Investor's Perspective: Hua yu Zhongtian currently has 1 product is declaring product listing applications, 2 varieties approved by the national "major new drug creation" science and technology major special projects, 5 varieties in clinical research.
    in the pipeline includes a new class 1 anti-tumor drug for different targets and mechanisms of action, such as ONCO-1, BG18, BG44, BGM57, BGMT8 and BGLP1.
    lead product expected to be available by the end of the year, Ukip, is genetically engineered to synthesize the Ebomycin-like.
    clinical Phase III study showed that for refroutable advanced breast cancer, which failed in yew alcohol and cyclocyclyc, Capertabin and Ukip can significantly improve OS, PFS, or ORR.
    so far, there are only a few late-stage breast cancer chemotherapy drugs that can significantly extend both PFS and OS, Ukip will offer new treatment options for patients with advanced breast cancer.
    In addition, the results of the previous studies show that Ukip's anti-tumor activity against common tumors such as breast cancer, lung cancer, liver cancer, bowel cancer and prostate cancer is better than that of yew alcohol, and it is also very effective for multi-drug-resistant tumors of yew alcohol and other chemotherapy drugs.
    the drug is expected to replace yew alcohol as a new mainstream chemotherapy drug in the future, and continues to be optimistic about the treatment prospects and market potential of Ukip.
    expects Ukip to bring more benefits to cancer patients.
    Private equity financing unknown Jun B-plus round: tens of millions of dollars investment institutions: (lead investment) Chunhua Capital, GaoYu Capital, (followed by investment) Five Source Capital, Junlian Capital, Yumei Capital, Yayi Capital Company Profile: Founded in 2017, located in Shenzhen.
    is an AI pharmaceutical company focused on intestinal micro-ecological, committed to intestinal micro-ecological based on AI technology, different from the traditional "cell-animal model-human" pharmaceutical research and development path, the company will be "artificial intelligence and bio-information analysis technology", combined with intestinal micro-ecological technology, improve the efficiency and success rate of new drugs.
    Private Equity Catamaran BioA Round: $42 million Investment Agency: Sofinnova Partners, Lightstone Ventures, SV Health Investors, Takeda Ventures, Astellas Venture Management, Inc.: Founded in 2020 in Cambridge, USA.
    is a cancer cell therapy developer that develops iso-car-NK cell therapies to treat cancer, with the aim of treating a variety of cancers, including solid tumors.
    developed the TAILWIND platform, which integrates proprietary features that take advantage of the natural anti-cancer properties of natural killer (NK) cells and enhance them through synthetic biology and NK cell engineering and manufacturing to create novel allogeneic CAR-NK cell therapies.
    Private Equity GT Medical Technologies B Round: $16 million Investment Agency: MVM Partners, MedTech Venture Partners, BlueStone Venture Partners, Inc.: Founded in 2017 in Arizona, USA.
    is a brain tumor target therapy developer dedicated to improving the health of patients with brain tumors, and its pioneering GammaTile™ therapy is an surgically targeted radiation therapy, and GT has achieved the effect of targeted treatment of brain tumors by combining the appropriate collagen substation with the seeds of brachytherapy (radiation).
    Private Equity Elevian B Round: $15 million Investment Agency: Prime Movers Lab, Bold Capital Partners, For Good Ventures, Kizoo Ventures, Lauder Partners, Longevity Fund, Sav Earth Fund, WTI, Inc.: Founded in 2017 in Massachusetts, USA.
    is an anti-aging product developer that develops potential drugs to treat and prevent age-related diseases and restore young regeneration.
    current focus areas of research include coronary artery disease, Alzheimer's disease, type 2 diabetes and muscle dysfunction (age-related muscle dysfunction).
    Private equity financing game Kohli bio-A-plus round: the transaction amount is not disclosed investment institutions: (lead investment) Huatai Zijin, (with investment) Haifu Investment, Xiaomiao Fund, Binghong Capital Company Profile: founded in 2015, located in Shanghai.
    is a leading enzyme engineering technology and genetic engineering technology of high-tech enterprises.
    research and development of biological catalytic and synthetic biology methods, and is committed to their application in large-scale production.
    widely used in medicine, health care products, pesticides and other fields, for the promotion and development of green chemistry has made a contribution.
    Private equity financing Yanhui Pharmaceutical B-round: the transaction amount is not disclosed investment institutions: Hanyu Capital, Power Capital, Jinpu Investment, Yin Shengtai Investment, Yanlian Health Fund Company Profile: The company was founded in 2005, located in Wuxi.
    company is a pharmaceutical sales company, the main sales of drugs, at the same time run the sale of various types of health food, personal care products, home medical equipment and other health products.
    company now has 15 large pharmacies and outpatient departments and other cooperative units, and has a number of health insurance fixed-point pharmacies.
    Private Equity Financing Warby Healthcare Round C: Hundreds of millions of yuan investment institutions: (lead investment) Gao Wei capital, (followed by investment) innovation engineering, Songbai Capital Company Profile: Founded in 2016, located in Shanghai.
    is a manufacturer of interventional products for cerebrovascular diseases, focusing on the field of neuro-intervention.
    At present, the layout of hemorrhagic stroke treatment and ischemic stroke treatment two areas, product pipeline covers including spring rings, thrombosis suction catheters, hydrant stents, dense mesh stents, balloons, wire guides and other products.
    Private Equity Financing Bosco Medical B Round: Hundreds of millions of yuan investment institutions: (lead investment) Shanghai Science venture capital group, GaoXuan Ventures, (with investment) Bo Bank Capital Company Profile: Founded in 2015, located in Shanghai.
    is a heart imaging product developer, focusing on cardiovascular quantitative blood flow fraction system research and development, its main products are coronary quantitative blood flow fraction (QFR) measurement system, QAngio CT, Medis Suite MR, QIvus, etc., to provide users with detection of tube cavity and vascular contouring, automated IVUS analysis and rapid editing, analysis of cardiovascular dimensions and morphology, cardiomyopathy and other services.
    investor's perspective: earlier this month, the National Health Insurance Administration's volume of procurement, once more than 10,000 yuan of crown bracket to an average of about 700 yuan.
    Hao Yue Capital believes that, with the end of the high-priced market for coronary stents, coronary interventional therapy is also in the transition from the previous pursuit of "surgical volume" to the pursuit of "surgical quality", with FKR, OCT, IVUS and other representative coronary functional diagnostic products in the "precision PCI" process is extremely important, while "intracvascular image evaluation and reduction" and other interventional implant-free treatment methods may continue to benefit from this collection, become the new mainstream of the future.
    FFR products are likely to be one of the biggest beneficiaries at this stage.
    FFR products from entering the domestic, the development has been not optimistic, 2019 domestic penetration rate of less than 1%, in addition to product and promotion issues, price and fees, and bracket competition is also an important reason.
    But after this coronary stent collection, compared to the vascular invasive FKR products, with the continuous updating of clinical recommendation guidelines, imaging FFR products do not account for the proportion of consumption, simple operation and other advantages will continue to be clinically welcomed, the domestic imaging FFR industry is likely to usher in a long-term golden development period, and BOT and other imaging FKR, CT-FFR, OCT/IVUS-FFR
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.